Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20820006 | 0.97 | ALDH1A1 (0.38) | ALDH1A1TSHRTDP1 | |
| SCHEMBL384233 | 0.97 | ALDH1A1 (0.38) | ALDH1A1TSHRTDP1 | |
| SCHEMBL386550 | 0.92 | — | — | |
| SCHEMBL129541 | 0.80 | — | — | |
| SCHEMBL386075 | 0.77 | — | — | |
| SCHEMBL7642498 | 0.76 | — | — | |
| SCHEMBL3169691 | 0.76 | TSHR (0.48) | ALDH1A1TSHRTDP1 | |
| SCHEMBL3148134 | 0.74 | TSHR (0.46) | ALDH1A1TSHRTDP1 | |
| SCHEMBL622797 | 0.74 | — | — | |
| SCHEMBL6843199 | 0.74 | CYP4F2 (0.41) | ALDH1A1TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101650-B2 | Method for treating a immunology-related disease | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-01-24 | — | — | US | disclosed |
| US-8067396-B2 | Amino alcohol compounds or phosphonic acid derivatives thereof | SANKYO COMPANY, LIMITED (JP) | 2011-11-29 | — | — | US | disclosed |
| US-7910617-B2 | Method for suppressing the number of peripheral blood lymphocytes using an amino alcohol compound | SANKYO COMPANY, LIMITED (JP) | 2011-03-22 | — | — | US | disclosed |
| US-20100035842-A1 | Amino alcohol compounds or phosphonic acid derivatives thereof | SANKYO COMPANY, LIMITED (JP) | 2010-02-11 | — | — | US | disclosed |
| US-20090326038-A1 | Method for treating a immunology-related disease | SANKYO COMPANY, LIMITED (JP) | 2009-12-31 | — | — | US | disclosed |
| US-7638551-B2 | Amino alcohol compounds or phosphonic acid derivatives thereof | SANKYO COMPANY, LIMITED (JP) | 2009-12-29 | — | — | US | disclosed |
| EP-1471054-B1 | AMINO ALCOHOL DERIVATIVE OR PHOSPHONIC ACID DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THESE | DAIICHI SANKYO CO LTD (JP) | 2009-07-01 | — | — | EP | disclosed |
| US-20070191468-A1 | Amino alcohol compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2007-08-16 | — | — | US | disclosed |
| US-20070142335-A1 | Amino alcohol compounds or phosphonic acid derivatives thereof | SANKYO COMPANY, LIMITED (JP) | 2007-06-21 | — | — | US | disclosed |
| US-20070105933-A1 | Amino alcohol compounds | SANKYO COMPANY, LIMITED (JP) | 2007-05-10 | — | — | US | disclosed |
| EP-1300405-B1 | AMINO ALCOHOL DERIVATIVES | SANKYO CO (JP) | 2007-04-18 | — | — | EP | disclosed |
| US-7199150-B2 | Amino alcohol compounds | SANKYO COMPANY, LIMITED (JP) | 2007-04-03 | — | — | US | disclosed |
| EP-1733724-A1 | AMINO ALCOHOL COMPOUND | Sankyo Company, Limited (JP) | 2006-12-20 | — | — | EP | disclosed |
| US-6964976-B2 | Amino alcohol derivatives | SANKYO COMPANY, LIMITED (JP) | 2005-11-15 | — | — | US | disclosed |
| US-20050043386-A1 | Amino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing these | SANKYO COMPANY, LIMITED (JP) | 2005-02-24 | — | — | US | disclosed |
| EP-1471054-A1 | AMINO ALCOHOL DERIVATIVE OR PHOSPHONIC ACID DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THESE | Sankyo Company, Limited (JP) | 2004-10-27 | — | — | EP | disclosed |
| US-20040132784-A1 | Amino alcohol derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-07-08 | — | — | US | disclosed |
| US-6723745-B2 | PREVENTION OR TREATMENT OF AUTOIMMUNE DISEASE IN WARM BLOODED ANIMAL | SANKYO COMPANY, LIMITED (JP) | 2004-04-20 | — | — | US | disclosed |
| US-20030236297-A1 | Amino alcohol derivatives | SANKYO COMPANY, LIMITED (JP) | 2003-12-25 | — | — | US | disclosed |
| EP-1300405-A1 | AMINO ALCOHOL DERIVATIVES | Sankyo Company, Limited (JP) | 2003-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236297-A1 | Amino alcohol derivatives | CD4, ADH1C, ADH1A | ALDH1A1 129/4885TSHR 1187/4885TDP1 3661/4885 |
| US-20050043386-A1 | Amino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing these | PHOSPHO1, CD4, FCGRT | ALDH1A1 945/4885TSHR 1254/4885TDP1 3885/4885 |
| US-20040132784-A1 | Amino alcohol derivatives | CD4, ADH1C, ADH1A | ALDH1A1 129/4885TSHR 1187/4885TDP1 3661/4885 |
| US-20090326038-A1 | Method for treating a immunology-related disease | C3AR1, HRH3, HRH2 | ALDH1A1 2821/4885TSHR 241/4885TDP1 4400/4885 |
| US-20070105933-A1 | Amino alcohol compounds | ADH1C, C9, SSB | ALDH1A1 582/4885TSHR 238/4885TDP1 3739/4885 |
| US-20070142335-A1 | Amino alcohol compounds or phosphonic acid derivatives thereof | HRH3, C3AR1, HRH4 | ALDH1A1 1443/4885TSHR 316/4885TDP1 3799/4885 |
| US-20070191468-A1 | Amino alcohol compound | ADH1A, ADH1C, BCAT1 | ALDH1A1 62/4885TSHR 1558/4885TDP1 1914/4885 |
| US-20100035842-A1 | Amino alcohol compounds or phosphonic acid derivatives thereof | PHOSPHO1, ADH1C, ADH1A | ALDH1A1 898/4885TSHR 744/4885TDP1 3477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.